OR WAIT null SECS
January 18, 2019
The new year has started with a bang in terms of mergers and acquisitions.
January 17, 2019
Univercells, a business-to-business provider focused on biologics, has commercially launched its proprietary bioproduction system, NevoLine.
A strategic collaboration has been formed between 4D pharma and The University of Texas MD Anderson Cancer Center.
Cell and gene therapy platform company, Locate Bio, has announced that it is set to receive key patents for its IntraStem technology covering the United States and Europe
Solentim and ATUM have announced a technology collaboration agreement that will focus on the creation of an efficient cell line development solution for biotherapeutic drug developers.
Lonza and Takeda have furthered their multiproduct partnership through collaborative efforts on a new cancer treatment-Alunbrig (brigatinib).
January 15, 2019
The agreement gives Sanofi access to Biomunex’s proprietary bi- and multi-specific-antibody-generating platform.
Sanofi’s Adacel (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis [Tdap] vaccine adsorbed) is approved for a repeat dose in people 10 through 64 years of age, 8 years or more after the first vaccination.
January 14, 2019
The company is set to expand biologics and fill/finish capacity at its biologics manufacturing sites in Madison, WI, and Bloomington, IN.
January 11, 2019
The companies will collaborate to improve the manufacturability for two of Sanofi’s biotherapeutics.